# A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

> **NCT02733042** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 106 (actual)

## Conditions studied

- Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab
- **DRUG:** Ibrutinib
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT02733042
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-11
- **Primary completion:** 2019-03-06
- **Final completion:** 2022-08-21
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02733042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02733042, "A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02733042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*